Direct-to-Consumer Erectile Dysfunction Medications: is the Convenience Worth the Cost?

Area of Science:

• Urology
• Health Economics
• Telemedicine

Background:

• Erectile dysfunction (ED) affects over 24% of men in the US, with privacy and access barriers common.
• Telemedicine and direct-to-consumer (DTC) platforms are increasingly used for ED care, promising discretion and convenience.
• Phosphodiesterase type 5 (PDE5) inhibitors are the primary pharmacotherapy for ED.

Purpose of the Study:

• To review recent literature (past five years) on the economics of PDE5 inhibitors.
• To evaluate the cost-effectiveness of PDE5 inhibitors obtained through DTC platforms versus traditional methods.

Main Methods:

• Systematic literature review of studies published in the last five years.
• Analysis of pricing models and patient cost comparisons for PDE5 inhibitors.

Main Results:

• DTC platforms provide convenience for accessing ED medications.
• PDE5 inhibitors are significantly more expensive on DTC platforms compared to brick-and-mortar pharmacies.
• Economic trade-offs and clinical limitations of DTC platforms for ED care exist.

Conclusions:

• DTC platforms can improve access to ED care but come with higher costs.
• Patients need transparent pricing to make informed decisions about ED treatment.
• Further research is needed to balance convenience, cost, and clinical needs for ED patients.